Clinical Trial Update: A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of efinopegdutide (MK-6024) in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Efinopegdutide (efinopegdutide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2023-11-15